Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab Long-Term Extension in Early RA
NCT01665430Phase 3Terminated
- Sponsor
- Roche
- Start
- Jul 2012
- Primary completion
- Feb 2015
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Roche. Primary endpoint: Percentage of Participants With Adverse Events (AEs), AEs of Special Interest and Serious Adverse Events (SAEs). Started Jul 2012; status: terminated.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01665430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01665430.